Enact Holdings, Inc. (ACT), the mortgage guaranty insurance powerhouse that emerged from its 2021 spin-off from Genworth Financial, continues to navigate a housing market shaped by interest rate gyrations and lingering post-pandemic effects. What began as a subsidiary providing credit risk management for mortgages has evolved into a standalone entity with a leaner operation—employee headcount dropping 16% from 503 in 2021 to 421 in 2024—driving impressive revenue per employee gains of nearly 29% over that span to $2.85 million. This efficiency story, paired with resilient profitability, positions Enact as a defensive play in financial services, though recent insider selling and tempered analyst forecasts add layers of intrigue to its trajectory.
Revenue Resilience Amid Market Headwinds
Revenue has painted a picture of steady expansion, climbing from $841 million in 2018 to a projected $1.24 billion in 2025, a compound annual growth rate of roughly 8% through the historical period. This growth accelerated post-2020, when COVID-19 lockdowns briefly pressured originations, but rebounded sharply: 2021 saw a 1% uptick to $1.12 billion, followed by a modest 2% dip in 2022 amid rising rates, then 5% growth to $1.15 billion in 2023 and another 4% to $1.20 billion in 2024. Revenue per share mirrors this, rising 25% from $6.72 in 2022 to $8.33 projected for 2025, underscoring share count reduction via buybacks—outstanding shares fell 4% from 163 million in 2022 to 156 million in 2024, and further to an estimated 144 million by 2026.
Why does this matter? In mortgage insurance, revenue ties directly to new insurance written (NIW) volumes, which correlate with home sales. Enact’s ability to grow amid Fed rate hikes (from near-zero in 2021 to over 5% by 2023) highlights market share gains, possibly from competitors like MGIC or Radian stumbling. However, analyst projections for 2026 and 2027 show a stark revenue contraction to around $80 million annually—a 93% plunge from 2025 levels. This could signal expectations of a prolonged housing slowdown, with high rates suppressing demand, or perhaps conservative modeling around policy changes like potential FHA fee adjustments.
Profitability: A Fortress of High Margins
Enact’s crown jewel is its profitability, with earnings before taxes (EBT) consistently above $850 million since 2022, up 43% from $472 million in 2020’s pandemic trough. Net income followed suit, peaking at $704 million in 2022 before stabilizing around $665-688 million through 2024. EBT margins hover in the mid-70% range (73% in 2023, 73% in 2024), far outpacing industry peers and reflecting the low-loss nature of mortgage guaranty—defaults remain subdued thanks to strong underwriting post-2008 reforms.
Gross margins tell a similar high-quality tale: averaging 75% from 2019-2025, with a 2022 spike to 88% likely from favorable loss reserve releases during the refi boom. Return on equity (ROE) at 14-19% through the period crushes the financial sector average (~10%), signaling efficient capital deployment. ROA and ROIC in the 10-13% ballpark further affirm this, as the company generates robust returns without heavy capex—per-share capex flat at zero, freeing up free cash flow per share that climbed 27% from $3.44 in 2022 to $4.39 in 2024.
Correlating this to stock performance, low/high price ranges expanded in tandem: from $18.76-$24 in 2021 (post-spin debut amid uncertainty) to $26-$37 in 2024, a 40%+ range widening that tracks earnings stability. The stock’s ascent reflects investor confidence in these margins as a buffer against housing cycles, much like how 2020’s EBT dip (down 34% to $472 million) coincided with the lowest prices.
Balance Sheet: Lean and Low-Risk
Enact’s fortress balance sheet features minimal net debt—peaking at $315 million in 2021 before halving to $144 million in 2024—and stable total debt around $740-745 million, or less than 10% of shareholders’ equity, which ballooned 22% from $4.10 billion in 2022 to $5.36 billion projected for 2025. Book value per share rose steadily 27% over three years to $36.09 by 2025, supporting a PB ratio near 1.0, a bargain for a high-ROE name.
Working capital swings highlight prudence: a $419 million negative in 2021 (aggressive underwriting?) flipped to $13 million positive in 2024. Cash flow operations surged 22% to $686 million in 2024, equating to free cash flow per share growth that bolsters buybacks and dividends. This low-leverage profile—net debt-to-EBT under 20%—proved vital during 2023’s regional bank scares (e.g., Silicon Valley Bank fallout), insulating Enact from liquidity crunches plaguing riskier lenders.
Valuation: Cheap on Fundamentals, But Signals Mixed
Trading at PE ratios of 6-9x earnings (7.4x in 2024), PS around 4x sales, and EV/FCF ~7-8x, Enact screams value relative to S&P 500 multiples (20x+ PE). EV/Sales ticked up to 4.8x projected for 2027, but still reasonable given 70%+ margins. Historically, the stock traded at a discount post-spin, widening as fundamentals strengthened—PB from 0.82x in 2020 to 1.07x in 2025.
Yet, insider activity clouds the narrative. Zero buys across 2025-2026, with sells totaling over $300 million in proceeds. A single 10% owner dominates, offloading 5-6 million shares monthly (e.g., 722k in March 2025 at escalating prices, up to 940k in October), reducing their stake from ~122 million to 114 million shares by early 2026. Executives chimed in too: CEO sold 33k shares in August 2025, a director 10k twice. Routine 10b5-1 plans? Possibly, but the volume—amid no buys—hints at profit-taking or caution on near-term housing woes.
Stock Performance: Aligned with Fundamentals, Room to Run?
The stock’s journey from 2021 lows to recent levels tracks fundamentals closely: a ~100% gain from inception lows correlates with 50%+ net income growth and share shrinkage. High prices climbed 32% from 2023 to 2024, mirroring revenue/emp efficiency. Versus the recent close, analyst targets imply modest upside—the mean about 2% higher, high 15% above, low 3% below—suggesting fair valuation but limited enthusiasm.
Looking Ahead: Steady Growth or Cycle Trap?
Analysts foresee EPS dipping to $0.31 in 2026 from $4.40 in 2024 (a 93% drop), aligning with that revenue cliff, potentially from normalizing cure rates or NIW contraction as rates stay elevated (Fed cuts delayed?). Yet, 2025 looks solid: revenue +3% to $1.24 billion, EPS stable, ROE ~13%. Longer-term, if housing rebounds—say, with 2026 rate cuts sparking originations—Enact’s scale (top-3 MI player) and pristine loss ratios could drive reacceleration.
Major events loom: the 2021 spin unlocked value (stock up 50% in first year), but 2022-2023 rate hikes crushed volumes industry-wide. Recent FTC scrutiny on non-competes (2024 ruling) might aid talent poaching for efficiency, while potential GSE privatization could reshape MI dynamics.
In sum, Enact’s narrative is one of understated strength—a cash-gushing machine trading cheap, with insiders cashing out amid cycle risks. Fundamentals scream buy for patient investors eyeing housing’s next leg up, but that revenue projection warrants watchfulness. At current multiples, it’s a storyteller’s dream: proven resilience meets uncertain chapters ahead.
(Word count: 1,128)